dc.contributor | PUCPR | |
dc.contributor | Universidade de São Paulo (USP) | |
dc.contributor | Universidade Federal do Rio de Janeiro (UFRJ) | |
dc.contributor | Clínica Gastrosaúde | |
dc.contributor | Clínica ESADI | |
dc.contributor | Hospital Nossa Senhora das Graças | |
dc.contributor | Universidade Estadual Paulista (Unesp) | |
dc.date.accessioned | 2018-12-11T17:34:49Z | |
dc.date.available | 2018-12-11T17:34:49Z | |
dc.date.created | 2018-12-11T17:34:49Z | |
dc.date.issued | 2017-10-01 | |
dc.identifier | Arquivos de Gastroenterologia, v. 54, n. 4, p. 321-327, 2017. | |
dc.identifier | 1678-4219 | |
dc.identifier | 0004-2803 | |
dc.identifier | http://hdl.handle.net/11449/179347 | |
dc.identifier | 10.1590/s0004-2803.201700000-51 | |
dc.identifier | S0004-28032017000400321 | |
dc.identifier | 2-s2.0-85033588876 | |
dc.identifier | S0004-28032017000400321.pdf | |
dc.identifier | 4734747821898178 | |
dc.description.abstract | Background – Adalimumab is a monoclonal antibody, tumor necrosis factor-alpha (TNFα) inhibitor that has efficacy for inducing and maintaining remission in moderate-to-severe ulcerative colitis. Real world studies with adalimumab in Latin American ulcerative colitis patients are scarce. Objective – To assess the clinical remission rates in induction and maintenance with adalimumab therapy in ulcerative colitis. Methods – Observational, multicenter and retrospective study on a case series of patients with moderate-to-severe ulcerative colitis under adalimumab therapy. The variables analyzed were: demographic data, previous infliximab status, concomitant drugs, the Montreal Classification, disease activity (Mayo score) at weeks 0, 8, 26 and 52, or until the last follow-up. Clinical remission was defined as a partial Mayo score ≤2 and Last observation carried forward (LOCF) and Non responder imputation (NRI) analysis were used. Results – Thirty-six patients were included in the study. With LOCF analysis, remission rates at weeks 8, 26 e 52 were of 41.7%, 47.2% and 47.2%, respectively. With NRI analysis, remission rates at weeks 8, 26 and 52 were of 41.7%, 41.7% and 27.8%, respectively. Conclusion – Adalimumab was effective in the treatment of moderate-to-severe ulcerative colitis. Clinical remission was observed in approximately 40% of the patients at weeks 8 and 26, and in almost a quarter of the patients after 1 year of follow up. | |
dc.language | eng | |
dc.relation | Arquivos de Gastroenterologia | |
dc.relation | 0,396 | |
dc.rights | Acesso aberto | |
dc.source | Scopus | |
dc.subject | Adalimumab | |
dc.subject | Inflammatory bowel diseases | |
dc.subject | Proctocolitis | |
dc.subject | Ulcerative colitis | |
dc.title | Adalimumabe no manejo da retocolite ulcerativa inespecífica: Resultados de um estudo multicêntrico observacional Brasileiro | |
dc.type | Artículos de revistas | |